Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | PKM | P14618 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19244073 | 1.00 | DNMT1 (0.73) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL1984728 | 0.96 | DNMT1 (0.75) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL3081901 | 0.96 | DNMT1 (0.75) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL2445932 | 0.96 | DNMT1 (0.75) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL4214992 | 0.91 | DNMT1 (0.75) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| Tryptophan SCHEMBL8845198 | 0.90 | KMT2A (0.71) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL3079234 | 0.89 | DNMT1 (0.59) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL3086724 | 0.89 | DNMT1 (0.59) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL16408816 | 0.87 | DNMT1 (0.57) | DNMT1KMT2APKMCYP2C19DNMT3B | |
| SCHEMBL17525785 | 0.87 | DNMT1 (0.57) | DNMT1KMT2APKMCYP2C19DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905763-B1 | N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS | NEBOLSIN VLADIMIR EVGENIEVICH (RU) | 2019-05-08 | — | — | EP | claimed |
| EP-3207932-A1 | DNA METHYLTRANSFERASE INHIBITORS FOR RETT SYNDROME THERAPY | Universität Stuttgart (DE) | 2017-08-23 | — | — | EP | claimed |
| US-8940780-B2 | N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents | OTKRYTOE AKTSIONERNOE OBSCHESTVO OTECHESTVENNYE LEKARSTVA (RU) | 2015-01-27 | — | — | US | claimed |
| US-20250295686-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4419209-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240125787-A1 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11874276-B2 | STING levels as a biomarker for cancer immunotherapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20210025893-A1 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2019195658-A1 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-1905763-B1 | N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS | NEBOLSIN VLADIMIR EVGENIEVICH (RU) | 2019-05-08 | — | — | EP | disclosed |
| EP-3207932-A1 | DNA METHYLTRANSFERASE INHIBITORS FOR RETT SYNDROME THERAPY | Universität Stuttgart (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-8940780-B2 | N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents | OTKRYTOE AKTSIONERNOE OBSCHESTVO OTECHESTVENNYE LEKARSTVA (RU) | 2015-01-27 | — | — | US | disclosed |
| US-8912185-B2 | Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-arrhythmic agents | Obschestvo S Ogranichennoi Otvetstvennostyu “Pharmenterprises” (RU) | 2014-12-16 | — | — | US | disclosed |
| US-20130324540-A1 | USE OF GLUTARIC ACID DERIVATIVES OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ANTI-ARRHYTHMIC AGENTS | Obschestvo Ogranichennoi Otvetstvennostyu "Pharmenterprises" (RU) | 2013-12-05 | — | — | US | disclosed |
| CN-101243053-B | N-acylamino acid derivatives, process for their preparation, pharmaceutical compositions and their use as antiallergic, antiinflammatory and hypolipidemic agents | OTKRYTOE AKTSIONERNOE OBSCHEST | 2012-08-08 | — | — | CN | disclosed |
| US-20110224213-A1 | Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "PHARMENTERPRISES" (RU) | 2011-09-15 | — | — | US | disclosed |
| US-20080319040-A1 | N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents | OTKRYTOE AKTSIONERNOE OBSCHESTVO "OTECHESTVENNYE LEKARSTVA (RU) | 2008-12-25 | — | — | US | disclosed |
| CN-101243053-A | N-acylamino acid derivatives, process for their preparation, pharmaceutical compositions and their use as antiallergic, antiinflammatory and hypolipidemic agents | OTKRYTOE AKTSIONERNOE OBSCHEST (RU) | 2008-08-13 | — | — | CN | disclosed |
| EP-1905763-A1 | N-ACYLIC AMINOACID DERIVATIVES. METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS | Nebolsin, Vladimir Evgenievich (RU) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324540-A1 | USE OF GLUTARIC ACID DERIVATIVES OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ANTI-ARRHYTHMIC AGENTS | GCDH, ALDH5A1, GLS2 | DNMT1 4646/4885KMT2A 2434/4885PKM 734/4885 |
| US-20110224213-A1 | Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents | GCDH, ALDH5A1, GLS2 | DNMT1 4646/4885KMT2A 2434/4885PKM 734/4885 |
| US-20080319040-A1 | N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents | HRH4, HRH2, AADAT | DNMT1 4804/4885KMT2A 1759/4885PKM 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.